is a monoclonal antibody

Indications: used for prophylaxis of acute rejection in allogeneic renal transplantation. It is given with cyclosporine and corticosteroid immunosuppression regimens.

Contraindicated: hypersensitivity to basiliximab or any other component of the formulation.

Cautions: off-label use in cardiac transplantation (increased risk of serious cardiac side effects including cardiac arrest, atrial flutter, and palpitations).

Pregnancy: Avoid (no information available) adequate contraception must be used during treatment and for 16 weeks after last dose.

Breast-feeding: Avoid (no information available).

Side-effects: severe hypersensitivity reactions and cytokine release syndrome have been reported

Dose By intravenous injection or by intravenous infusion: 20 mg within 2 hours before transplant surgery and 20 mg 4 days after surgery. withhold second dose if severe hypersensitivity or graft loss occurs. CHILD and ADOLESCENT 1–17 years: body-weight under 35 kg, 10 mg within 2 hours before transplant surgery and 10 mg 4 days after surgery; body-weight over 35 kg, adult dose.